BEVACIZUMABE INTRA-VÍTREO: ANÁLISE DA TOXICIDADE RETINIANA APÓS 3 MESES EM OLHOS DE COELHOS NÃO ALBINOS
Autor(a) principal: | |
---|---|
Data de Publicação: | 2009 |
Tipo de documento: | Tese |
Idioma: | por |
Título da fonte: | Repositório Institucional da UFG |
Texto Completo: | http://repositorio.bc.ufg.br/tede/handle/tde/1550 |
Resumo: | Antiangiogenesis therapy has become a first-line treatment for neovascular age-related macular degeneration (AMD). Bevacizumab has proven to be efficient and cost effective, however its use in AMD is still off-label. PURPOSES: Evaluating the histological toxicity of bevacizumab on the neurosensorial retina (NSR) and the retinal pigmented epithelium (RPE) in pigmented rabbit eyes; evaluating if a fast increase in vitreous volume after a 0.1 ml balanced saline solution (BSS) intravitreal injection (IVI) in a rabbit eye will lead to histological damages in the NSR and RPE; and evaluating postoperative clinical complications after an IVI in rabbits eyes. METHODS: Eighteen pigmented rabbits (36 eyes) were divided into 4 groups a Control Group (3 rabbits - 6 eyes), which did not receive any IVI; the rabbits were sacrificed at the beginning of the study. Thirty eyes of the fifteen remaining rabbits were distributed to three groups: a sham group (S), that received a 0.1 ml balanced saline solution (BSS) IVI (ten eyes); group 1, that received a 1.25 mg (0.1 ml) bevacizumab IVI (ten eyes); and group 2, that received a 2.5 mg (0.1 ml) bevacizumab IVI (ten eyes). Postoperative clinical evaluation included inspection of the anterior segment and indirect binocular ophthalmoscopy. The rabbits were sacrificed 90 days after the procedure and both eyes of all the rabbits were enucleated. Histological examination of the NSR and RPE were performed and their morphological features and layer thickness were analyzed. RESULTS: No significant postoperative clinical complications were observed either in the neurossensorial retina or in the RPE. Histological morphology and thickness of the NSR and RPE layers did not differ significantly between BBS-injected eyes and bevacizumab-injected eyes. CONCLUSIONS: A rapid increase in vitreous volume, after 0.1 ml BSS IVI did not lead to any histological damage in the NSR and RPE in rabbit eyes. After a 90-day follow-up period, a single Bevacizumab 1.25 and 2.5 mg intravitreal injection did not lead any toxic damage in the NSR and RPE. No important postoperative complications in pigmented rabbit eyes were observed and it appears to be a safe procedure for the treatment of retinal neovascular diseases |
id |
UFG-2_c667b88821a90912458b2edac6e5f7d7 |
---|---|
oai_identifier_str |
oai:repositorio.bc.ufg.br:tde/1550 |
network_acronym_str |
UFG-2 |
network_name_str |
Repositório Institucional da UFG |
repository_id_str |
|
spelling |
ÁVILA, Marcos Pereira dehttp://lattes.cnpq.br/3335187297522447http://lattes.cnpq.br/5421665987351244ARRAES, João Carlos Diniz2014-07-29T15:25:22Z2009-08-312009-06-19ARRAES, João Carlos Diniz. Bevacizumab INTRA-VITREOUS: ANALYSIS OF RETINAL TOXICITY AFTER 3 MONTHS IN EYES OF RABBITS NOT ALBINO. 2009. 123 f. Tese (Doutorado em Ciencias da Saude) - Universidade Federal de Goiás, Goiânia, 2009.http://repositorio.bc.ufg.br/tede/handle/tde/1550ark:/38995/001300000918jAntiangiogenesis therapy has become a first-line treatment for neovascular age-related macular degeneration (AMD). Bevacizumab has proven to be efficient and cost effective, however its use in AMD is still off-label. PURPOSES: Evaluating the histological toxicity of bevacizumab on the neurosensorial retina (NSR) and the retinal pigmented epithelium (RPE) in pigmented rabbit eyes; evaluating if a fast increase in vitreous volume after a 0.1 ml balanced saline solution (BSS) intravitreal injection (IVI) in a rabbit eye will lead to histological damages in the NSR and RPE; and evaluating postoperative clinical complications after an IVI in rabbits eyes. METHODS: Eighteen pigmented rabbits (36 eyes) were divided into 4 groups a Control Group (3 rabbits - 6 eyes), which did not receive any IVI; the rabbits were sacrificed at the beginning of the study. Thirty eyes of the fifteen remaining rabbits were distributed to three groups: a sham group (S), that received a 0.1 ml balanced saline solution (BSS) IVI (ten eyes); group 1, that received a 1.25 mg (0.1 ml) bevacizumab IVI (ten eyes); and group 2, that received a 2.5 mg (0.1 ml) bevacizumab IVI (ten eyes). Postoperative clinical evaluation included inspection of the anterior segment and indirect binocular ophthalmoscopy. The rabbits were sacrificed 90 days after the procedure and both eyes of all the rabbits were enucleated. Histological examination of the NSR and RPE were performed and their morphological features and layer thickness were analyzed. RESULTS: No significant postoperative clinical complications were observed either in the neurossensorial retina or in the RPE. Histological morphology and thickness of the NSR and RPE layers did not differ significantly between BBS-injected eyes and bevacizumab-injected eyes. CONCLUSIONS: A rapid increase in vitreous volume, after 0.1 ml BSS IVI did not lead to any histological damage in the NSR and RPE in rabbit eyes. After a 90-day follow-up period, a single Bevacizumab 1.25 and 2.5 mg intravitreal injection did not lead any toxic damage in the NSR and RPE. No important postoperative complications in pigmented rabbit eyes were observed and it appears to be a safe procedure for the treatment of retinal neovascular diseasesA terapia anti-angiogênica tornou-se o tratamento de primeira linha para a forma neovascular da degeneração macular relacionada à idade. O Bevacizumabe é uma droga com boa eficácia e custo-efetividade, porém seu uso nesta doença ainda é considerado off-label. OBJETIVOS: Avaliar a toxicidade sobre a retina neurossensorial (RNS) e epitélio pigmentado da retina (EPR) da injeção intra-vítrea (IV) de bevacizumabe em olhos de coelhos não albinos; avaliar se o aumento súbito do volume vítreo após a injeção IV de 0,1ml de solução salina balanceada (SSB) no olho do coelho leva a danos histológicos na RNS e EPR; e avaliar as complicações clínicas pós-operatórias após a injeção IV em olhos de coelhos. MÉTODOS: 18 coelhos não albinos (36 olhos) foram distribuídos em 4 grupos. O grupo controle (3 coelhos 6 olhos), o qual não recebeu injeção IV, foi sacrificado no início do estudo. Os trinta olhos dos 15 coelhos restantes foram distribuídos em 3 grupos (1:1:1): Grupo Placebo (injeção IV de 0,1ml de SSB); Grupo 1 (injeção IV de 1,25mg/0,1ml de bevacizumabe); e Grupo 2 (injeção IV de 2,5mg/0,1ml de bevacizumabe). Os coelhos foram acompanhados por um período de 90 dias após o procedimento, quando então foram submetidos a eutanásia. Todos os coelhos tiveram seus olhos enucleados e avaliados histologicamente. Foram realizadas avaliação clínica pós-operatória (inspeção do segmento anterior e oftalmoscopia binocular indireta) e avaliação histológica da morfologia e da espessura das camadas da RNS e EPR. RESULTADOS: Não foram observadas complicações clínicas pós-operatórias significantes. A morfologia histológica e espessura das camadas da RNS e EPR não apresentou diferença significante entre os grupos controle e placebo, grupo placebo e grupo 1 e grupo placebo e grupo 2. CONCLUSÕES: A injeção IV de 1,25mg/0,1ml e 2,5mg/0,1ml bevacizumabe não leva a alterações histológicas tóxicas na RNS e EPR, nem a complicações clínicas pós-operatórias importantes em olhos de coelhos não albinos. A injeção IV de 0,1ml de SSB não leva a danos histológicos ao RNS e ao EPR em olhos de coelhos não albinosMade available in DSpace on 2014-07-29T15:25:22Z (GMT). No. of bitstreams: 1 tese joao arraes ciencias saude.pdf: 3252483 bytes, checksum: be116024cf6d2b2b6cef094fc736420d (MD5) Previous issue date: 2009-06-19application/pdfhttp://repositorio.bc.ufg.br/TEDE/retrieve/4203/tese%20joao%20arraes%20ciencias%20saude.pdf.jpgporUniversidade Federal de GoiásDoutorado em Ciencias da SaudeUFGBRCiencias da SaudeInibidores da AngiogêneseDegeneração MacularNeovascularização PatológicaMácula LúteaDrogas Anti-Angiogênicas/ToxicidadeBevacizumabeAngiogenesis InhibitorsMacular DegenerationNeovascularization, PathologicMacula LuteaAntiangiogenic drugs/ToxicityBevacizumabCNPQ::CIENCIAS DA SAUDEBEVACIZUMABE INTRA-VÍTREO: ANÁLISE DA TOXICIDADE RETINIANA APÓS 3 MESES EM OLHOS DE COELHOS NÃO ALBINOSBevacizumab INTRA-VITREOUS: ANALYSIS OF RETINAL TOXICITY AFTER 3 MONTHS IN EYES OF RABBITS NOT ALBINOinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/doctoralThesisinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFGinstname:Universidade Federal de Goiás (UFG)instacron:UFGORIGINALtese joao arraes ciencias saude.pdfapplication/pdf3252483http://repositorio.bc.ufg.br/tede/bitstreams/a2c5e8cc-e5ca-4868-8109-b756ed6f3c09/downloadbe116024cf6d2b2b6cef094fc736420dMD51THUMBNAILtese joao arraes ciencias saude.pdf.jpgtese joao arraes ciencias saude.pdf.jpgGenerated Thumbnailimage/jpeg2598http://repositorio.bc.ufg.br/tede/bitstreams/705548b1-2001-480c-840a-0a0f102d98f0/downloada4afe391c910521ba1dd62c9d1e2d6d1MD52tde/15502014-07-30 03:12:14.96open.accessoai:repositorio.bc.ufg.br:tde/1550http://repositorio.bc.ufg.br/tedeRepositório InstitucionalPUBhttp://repositorio.bc.ufg.br/oai/requesttasesdissertacoes.bc@ufg.bropendoar:2014-07-30T06:12:14Repositório Institucional da UFG - Universidade Federal de Goiás (UFG)false |
dc.title.por.fl_str_mv |
BEVACIZUMABE INTRA-VÍTREO: ANÁLISE DA TOXICIDADE RETINIANA APÓS 3 MESES EM OLHOS DE COELHOS NÃO ALBINOS |
dc.title.alternative.eng.fl_str_mv |
Bevacizumab INTRA-VITREOUS: ANALYSIS OF RETINAL TOXICITY AFTER 3 MONTHS IN EYES OF RABBITS NOT ALBINO |
title |
BEVACIZUMABE INTRA-VÍTREO: ANÁLISE DA TOXICIDADE RETINIANA APÓS 3 MESES EM OLHOS DE COELHOS NÃO ALBINOS |
spellingShingle |
BEVACIZUMABE INTRA-VÍTREO: ANÁLISE DA TOXICIDADE RETINIANA APÓS 3 MESES EM OLHOS DE COELHOS NÃO ALBINOS ARRAES, João Carlos Diniz Inibidores da Angiogênese Degeneração Macular Neovascularização Patológica Mácula Lútea Drogas Anti-Angiogênicas/Toxicidade Bevacizumabe Angiogenesis Inhibitors Macular Degeneration Neovascularization, Pathologic Macula Lutea Antiangiogenic drugs/Toxicity Bevacizumab CNPQ::CIENCIAS DA SAUDE |
title_short |
BEVACIZUMABE INTRA-VÍTREO: ANÁLISE DA TOXICIDADE RETINIANA APÓS 3 MESES EM OLHOS DE COELHOS NÃO ALBINOS |
title_full |
BEVACIZUMABE INTRA-VÍTREO: ANÁLISE DA TOXICIDADE RETINIANA APÓS 3 MESES EM OLHOS DE COELHOS NÃO ALBINOS |
title_fullStr |
BEVACIZUMABE INTRA-VÍTREO: ANÁLISE DA TOXICIDADE RETINIANA APÓS 3 MESES EM OLHOS DE COELHOS NÃO ALBINOS |
title_full_unstemmed |
BEVACIZUMABE INTRA-VÍTREO: ANÁLISE DA TOXICIDADE RETINIANA APÓS 3 MESES EM OLHOS DE COELHOS NÃO ALBINOS |
title_sort |
BEVACIZUMABE INTRA-VÍTREO: ANÁLISE DA TOXICIDADE RETINIANA APÓS 3 MESES EM OLHOS DE COELHOS NÃO ALBINOS |
author |
ARRAES, João Carlos Diniz |
author_facet |
ARRAES, João Carlos Diniz |
author_role |
author |
dc.contributor.advisor1.fl_str_mv |
ÁVILA, Marcos Pereira de |
dc.contributor.advisor1Lattes.fl_str_mv |
http://lattes.cnpq.br/3335187297522447 |
dc.contributor.authorLattes.fl_str_mv |
http://lattes.cnpq.br/5421665987351244 |
dc.contributor.author.fl_str_mv |
ARRAES, João Carlos Diniz |
contributor_str_mv |
ÁVILA, Marcos Pereira de |
dc.subject.por.fl_str_mv |
Inibidores da Angiogênese Degeneração Macular Neovascularização Patológica Mácula Lútea Drogas Anti-Angiogênicas/Toxicidade Bevacizumabe |
topic |
Inibidores da Angiogênese Degeneração Macular Neovascularização Patológica Mácula Lútea Drogas Anti-Angiogênicas/Toxicidade Bevacizumabe Angiogenesis Inhibitors Macular Degeneration Neovascularization, Pathologic Macula Lutea Antiangiogenic drugs/Toxicity Bevacizumab CNPQ::CIENCIAS DA SAUDE |
dc.subject.eng.fl_str_mv |
Angiogenesis Inhibitors Macular Degeneration Neovascularization, Pathologic Macula Lutea Antiangiogenic drugs/Toxicity Bevacizumab |
dc.subject.cnpq.fl_str_mv |
CNPQ::CIENCIAS DA SAUDE |
description |
Antiangiogenesis therapy has become a first-line treatment for neovascular age-related macular degeneration (AMD). Bevacizumab has proven to be efficient and cost effective, however its use in AMD is still off-label. PURPOSES: Evaluating the histological toxicity of bevacizumab on the neurosensorial retina (NSR) and the retinal pigmented epithelium (RPE) in pigmented rabbit eyes; evaluating if a fast increase in vitreous volume after a 0.1 ml balanced saline solution (BSS) intravitreal injection (IVI) in a rabbit eye will lead to histological damages in the NSR and RPE; and evaluating postoperative clinical complications after an IVI in rabbits eyes. METHODS: Eighteen pigmented rabbits (36 eyes) were divided into 4 groups a Control Group (3 rabbits - 6 eyes), which did not receive any IVI; the rabbits were sacrificed at the beginning of the study. Thirty eyes of the fifteen remaining rabbits were distributed to three groups: a sham group (S), that received a 0.1 ml balanced saline solution (BSS) IVI (ten eyes); group 1, that received a 1.25 mg (0.1 ml) bevacizumab IVI (ten eyes); and group 2, that received a 2.5 mg (0.1 ml) bevacizumab IVI (ten eyes). Postoperative clinical evaluation included inspection of the anterior segment and indirect binocular ophthalmoscopy. The rabbits were sacrificed 90 days after the procedure and both eyes of all the rabbits were enucleated. Histological examination of the NSR and RPE were performed and their morphological features and layer thickness were analyzed. RESULTS: No significant postoperative clinical complications were observed either in the neurossensorial retina or in the RPE. Histological morphology and thickness of the NSR and RPE layers did not differ significantly between BBS-injected eyes and bevacizumab-injected eyes. CONCLUSIONS: A rapid increase in vitreous volume, after 0.1 ml BSS IVI did not lead to any histological damage in the NSR and RPE in rabbit eyes. After a 90-day follow-up period, a single Bevacizumab 1.25 and 2.5 mg intravitreal injection did not lead any toxic damage in the NSR and RPE. No important postoperative complications in pigmented rabbit eyes were observed and it appears to be a safe procedure for the treatment of retinal neovascular diseases |
publishDate |
2009 |
dc.date.available.fl_str_mv |
2009-08-31 |
dc.date.issued.fl_str_mv |
2009-06-19 |
dc.date.accessioned.fl_str_mv |
2014-07-29T15:25:22Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/doctoralThesis |
format |
doctoralThesis |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
ARRAES, João Carlos Diniz. Bevacizumab INTRA-VITREOUS: ANALYSIS OF RETINAL TOXICITY AFTER 3 MONTHS IN EYES OF RABBITS NOT ALBINO. 2009. 123 f. Tese (Doutorado em Ciencias da Saude) - Universidade Federal de Goiás, Goiânia, 2009. |
dc.identifier.uri.fl_str_mv |
http://repositorio.bc.ufg.br/tede/handle/tde/1550 |
dc.identifier.dark.fl_str_mv |
ark:/38995/001300000918j |
identifier_str_mv |
ARRAES, João Carlos Diniz. Bevacizumab INTRA-VITREOUS: ANALYSIS OF RETINAL TOXICITY AFTER 3 MONTHS IN EYES OF RABBITS NOT ALBINO. 2009. 123 f. Tese (Doutorado em Ciencias da Saude) - Universidade Federal de Goiás, Goiânia, 2009. ark:/38995/001300000918j |
url |
http://repositorio.bc.ufg.br/tede/handle/tde/1550 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Federal de Goiás |
dc.publisher.program.fl_str_mv |
Doutorado em Ciencias da Saude |
dc.publisher.initials.fl_str_mv |
UFG |
dc.publisher.country.fl_str_mv |
BR |
dc.publisher.department.fl_str_mv |
Ciencias da Saude |
publisher.none.fl_str_mv |
Universidade Federal de Goiás |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFG instname:Universidade Federal de Goiás (UFG) instacron:UFG |
instname_str |
Universidade Federal de Goiás (UFG) |
instacron_str |
UFG |
institution |
UFG |
reponame_str |
Repositório Institucional da UFG |
collection |
Repositório Institucional da UFG |
bitstream.url.fl_str_mv |
http://repositorio.bc.ufg.br/tede/bitstreams/a2c5e8cc-e5ca-4868-8109-b756ed6f3c09/download http://repositorio.bc.ufg.br/tede/bitstreams/705548b1-2001-480c-840a-0a0f102d98f0/download |
bitstream.checksum.fl_str_mv |
be116024cf6d2b2b6cef094fc736420d a4afe391c910521ba1dd62c9d1e2d6d1 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFG - Universidade Federal de Goiás (UFG) |
repository.mail.fl_str_mv |
tasesdissertacoes.bc@ufg.br |
_version_ |
1811721460245331968 |